echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > CDK1: Occupies an important site of signal transduction, clinically refers to pancreatic cancer & glioma!

    CDK1: Occupies an important site of signal transduction, clinically refers to pancreatic cancer & glioma!

    • Last Update: 2021-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cyclin-dependent kinase (CDK) is one of the important members of the protein kinase family; among them, CDK1 plays a key role in cell cycle regulation, checkpoint activation, and DNA damage repair


    Important cell signaling site

    Important cell signaling site

    Tumor cells are characterized by continuous division and uncontrolled proliferation.


    There are many studies on whether the functions of CDKs are dependent and replaceable, especially CDK1 vs CDK2


    In addition, CDK1 can completely compensate for the loss of CDK2 in terms of cell cycle regulation.


    Figure 1.


    Disease location: pancreatic cancer & glioma

    Disease location: pancreatic cancer & glioma

    At present, the development of clinical indications for CDK1 inhibitors is mainly focused on pancreatic cancer and glioma, especially pancreatic cancer


    Pancreatic cancer is known as the "king of cancer".


    The treatment of pancreatic cancer mainly includes surgical treatment, radiotherapy and chemotherapy


    Figure 2.


    Clinical drugs: up to stage III

    Clinical drugs: up to stage III

    Up to now, through database query, no drugs developed for CDK1 have been marketed, and the highest clinical progress is clinical phase III, such as Rigosertib (Phase III), BEY-1107 (Phase II), Zotiraciclib (Phase II), etc.


    ➢ Rigosertib (Phase III)

    First of all, this is a pan-target inhibitor developed by Onconova Therapeutics for the treatment of first-line high-risk myelodysplastic syndrome (MDS) in combination with azacitidine


    ➢ BEY-1107 (Phase II)

    The development company is Beyondbio, which is a CDK1 inhibitor and is clinically used in the treatment of pancreatic cancer


    ➢ Zotiraciclib (Phase II)

    The development company is Adastra Pharmaceuticals, an oral brain-penetrating multikinase inhibitor, and also a multi-target inhibitor, especially targeting CDK1/2/5/7/9, which is clinically directed towards glioblastoma and interstitial Treatment of degenerative astrocyte tumors


    Patent applications in China

    Patent applications in China

    Through domestic patent inquiries, the CDK1 inhibitor-related patents applied in China are related to tumors.


    Shandong University applied for the invention patent "Cyclin-dependent kinase 1 inhibitor and its use" in 2011.


    The Chinese Academy of Medical Sciences Peking Union Medical College Hospital applied for the invention patent "Cyclin-dependent kinase 1 inhibitor and its use" in 2019.


    references:

    1.
    Burden of Pancreatic Cancer: From Epidemiology to Practice.
    Clinical Gastroenterology and Hepatology 2020.
    doi.
    org/10.
    1016/j.
    cgh.
    2020.
    02.
    054

    2.
    Research on the mechanism of cyclin-dependent kinase 1 promoting DNA synthesis and mediating tumor cell chemotherapy resistance.
    CNKI

    3.
    CN102019000441888C

    4.
    CN102011000146236C

    5.
    Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy.
    doi.
    org/10.
    1016/j.
    apsb.
    2021.
    01.
    002

    6.
    Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    doi.
    org/10.
    1016/j.
    phrs.
    2018.
    11.
    035

    7.
    Cell cycle regulators in cancer cell metabolism.
    BBA-Molecular Basis of Disease.
    doi.
    org/10.
    1016/j.
    bbadis.
    2020.
    165715

    8.
    Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
    European Journal of Medicinal Chemistry.
    DOI: 10.
    1016/j.
    ejmech.
    2017.
    08.
    071

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.